Hiscox Ltd Share Price London S.E.
Equities
HSX
BMG4593F1124
Property & Casualty Insurance
End-of-day quote
Other stock markets
|
||
- GBP | - |
05-08 | UBS raises Centrica to 'buy' from 'neutral | AN |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
Sales 2024 * | 3.89B 4.94B 389B | Sales 2025 * | 4.27B 5.42B 427B | Capitalization | 4B 5.08B 400B |
---|---|---|---|---|---|
Net income 2024 * | 469M 595M 46.9B | Net income 2025 * | 504M 640M 50.4B | EV / Sales 2024 * | 1.03 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.94 x |
P/E ratio 2024 * |
8.58
x | P/E ratio 2025 * |
7.87
x | Employees | - |
Yield 2024 * |
2.77% | Yield 2025 * |
3.07% | Free-Float | 97.42% |
Latest transcript on Hiscox Ltd
Managers | Title | Age | Since |
---|---|---|---|
Hamayou Hussain
CEO | Chief Executive Officer | 51 | 21/04/16 |
Paul Cooper
DFI | Director of Finance/CFO | 52 | 11/05/22 |
Stéphane Flaquet
COO | Chief Operating Officer | - | 28/02/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 15/11/17 | |
Jonathan Bloomer
CHM | Chairman | 70 | 31/05/23 |
Anne MacDonald
BRD | Director/Board Member | 68 | 19/05/15 |
1st Jan change | Capi. | |
---|---|---|
+47.44% | 64.45B | |
+14.23% | 52.37B | |
+11.28% | 49.59B | |
+16.87% | 43.85B | |
+36.93% | 38.41B | |
+71.75% | 31.82B | |
+11.64% | 29.67B | |
+26.73% | 25.57B | |
+2.15% | 22.1B |
- Stock Market
- Equities
- HSX Stock
- HSX Stock